Fujiwaki Takehisa, Matama Chihiro, Kobayashi Hironori, Sejima Hitoshi
Department of Pediatrics, Matsue Red Cross Hospital, Matsue 690-8506, Japan.
Department of Pediatrics, Shimane University Faculty of Medicine, Izumo 693-8501, Japan.
Yonago Acta Med. 2024 May 22;67(2):169-175. doi: 10.33160/yam.2024.05.011. eCollection 2024 May.
We report a 1-year-7-month-old boy with West syndrome who had associated secondary adrenal insufficiency as a side effect of synthetic ACTH therapy. Serial investigation using corticotropin-releasing hormone (CRH) stimulation tests revealed the time course of his hypothalamic-pituitary-adrenal (HPA) axis recovery after the secondary adrenal insufficiency. Three days after completion of the ACTH therapy, the basal cortisol, peak cortisol, and peak ACTH levels were all low. One month after ACTH therapy, the basal cortisol level exceeded the cutoff level for intact adrenocortical function, and the peak ACTH level had improved. Five months after ACTH therapy, the peak cortisol level exceeded the cutoff level for intact adrenocortical function. The secondary adrenal insufficiency after ACTH therapy and the four months' time lag between the recovery timing of the basal and peak cortisol levels on CRH stimulation tests were notable findings. This follow-up data is valuable information for understanding the timeline for the process of recovery of the HPA axis from secondary adrenal insufficiency, that should lead to appropriate protocols for adrenal testing and adrenocorticosteroid replacement for patients who have undergone ACTH therapy. We also reviewed previous studies on secondary adrenal insufficiency after ACTH therapy in terms of incidence rate, onset risk factors, and recovery from it. Based on our own experience and previous reports, we suggest secondary adrenal insufficiency after ACTH therapy as follows: regarding the total synthetic ACTH dose administered, approximately 0.2 mg/kg of ACTH could cause secondary adrenal insufficiency. As for the required period for convalescence from secondary adrenal insufficiency, it would take from two to five months.
我们报告了一名1岁7个月大患有韦斯特综合征的男孩,其因合成促肾上腺皮质激素(ACTH)治疗出现继发性肾上腺功能不全这一副作用。使用促肾上腺皮质激素释放激素(CRH)刺激试验进行的系列调查揭示了继发性肾上腺功能不全后其下丘脑 - 垂体 - 肾上腺(HPA)轴恢复的时间进程。ACTH治疗结束三天后,基础皮质醇、皮质醇峰值和促肾上腺皮质激素峰值水平均较低。ACTH治疗一个月后,基础皮质醇水平超过了肾上腺皮质功能完整的临界水平,促肾上腺皮质激素峰值水平有所改善。ACTH治疗五个月后,皮质醇峰值水平超过了肾上腺皮质功能完整的临界水平。ACTH治疗后的继发性肾上腺功能不全以及CRH刺激试验中基础和皮质醇峰值水平恢复时间之间四个月的时间间隔是显著发现。这些随访数据对于理解HPA轴从继发性肾上腺功能不全恢复过程的时间线是有价值的信息,这应该会为接受ACTH治疗的患者制定合适的肾上腺检测和肾上腺皮质类固醇替代方案。我们还从发病率、发病危险因素及恢复情况等方面回顾了先前关于ACTH治疗后继发性肾上腺功能不全的研究。基于我们自己的经验和先前的报告,我们对ACTH治疗后的继发性肾上腺功能不全提出如下建议:关于所给予的合成ACTH总剂量,约0.2mg/kg的ACTH可能会导致继发性肾上腺功能不全。至于继发性肾上腺功能不全康复所需时间,需要两到五个月。